A Phase 2 Switch Maintenance Study of MRx0518 and Avelumab in Patients With Unresectable Locally Advanced or Metastatic Urothelial Carcinoma Who Did Not Progress on First-Line Platinum-Containing Chemotherapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 20 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; CJRB 102 (Primary)
Indications Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Acronyms AVENU
Sponsors 4D Pharma PLC

Most Recent Events

14 Apr 2023 Planned End Date changed from 1 Jan 2024 to 1 Apr 2023.
14 Apr 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Apr 2023.
14 Apr 2023 Planned initiation date changed from 1 Feb 2022 to 1 Mar 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight